# US 2025/0144036 A1 · Compounds and compositions for delivery of therapeutic agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144036 A1
- Document ID: US20250144036A1
- Status: Published application
- Kind: A1
- Application number: 18/716,220
- Filed: 2022-12-09
- Published: 2025-05-08
- Earliest claimed: 2021-12-10
- Assignees: ModernaTX, Inc.
- Applicants: ModernaTX, Inc.
- Inventors: Kerry E. BENENATO; Juneyoung LEE; Mohindra SEEPERSAUD
- Web page: https://patentgrep.com/patent/US20250144036A1

## CPC

- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- C07C 229/16: to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- C07C 229/06: having only one amino and one carboxyl group bound to the carbon skeleton
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel cationic lipid as well as additional lipids such as ionizable lipids, phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

## Claims

### Claim 1

A cationic lipid of Formula (I):
or an isomer thereof, wherein:
R′x is:
R′y is:
and R′z is:
wherein
denotes a point of attachment;
Rxα, Rxγ, Rxγ, and Rxδ are each independently selected from the group consisting of H, C1-12 alkyl, and C2-12 alkenyl;
Ryα, Ryβ, Ryγ, and Ryδ are each independently selected from the group consisting of H, C1-12 alkyl, and C2-12 alkenyl;
Rzα, Rzβ, Rzγ, and Rzδ are each independently selected from the group consisting of H, C1-12 alkyl, and C2-12 alkenyl;
RH is —(CH2)qOH, wherein q is selected from 1, 2, 3, 4, and 5;
each RT is independently selected from C1-12 alkyl and C2-12 alkenyl;
a is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9;
b is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9;
c is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9; and
A− is any pharmaceutically acceptable anion.

### Claim 2 (depends on 1)

The cationic lipid of claim 1, wherein
R′x is
R′y is:
and
R′z is:
wherein
denotes a point of attachment;
Rxγ is selected from the group consisting of H, C1-12 alkyl, and C2-12 alkenyl;
Ryγ is selected from the group consisting of H, C1-12 alkyl, and C2-12 alkenyl;
Rzγ is selected from the group consisting of H, C1-12 alkyl, and C2-12 alkenyl; and
R2a, R2b, R2c, R3a, R3b, and R3c are each independently selected from the group consisting of C1-14 alkyl and C2-14 alkenyl.

### Claim 3 (depends on 1)

The cationic lipid of claim 1, wherein
R′a is:
R′b is:
and R′c is:
wherein
denotes a point of attachment;
R′xγ is selected from the group consisting of H, C1-12 alkyl, and C2-12 alkenyl;
Ryγ is selected from the group consisting of H, C1-12 alkyl, and C2-12 alkenyl; and
R2c and R3c are each independently selected from the group consisting of C1-14 alkyl and C2-14 alkenyl.

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein Rxγ and Ryγ are each H.

### Claim 5 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein Rxγ and Ryγ are each C1-12 alkyl or C2-12 alkenyl.

### Claim 6 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein R7 is C1-12 alkyl or C2-12 alkenyl and Ryγ is H.

### Claim 7

The compound of any one of the preceding claims, wherein q is 2.

### Claim 8 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein the compound is selected from:

### Claim 9

The compound of any one of the preceding claims, wherein A− is selected from chloride, bromide, iodide, hydroxide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate, and acetate.

### Claim 10

The compound of any one of the preceding claims, wherein A− is selected from bromide, chloride, and hydroxide.

### Claim 11

An empty lipid nanoparticle (empty LNP) comprising a cationic lipid of any one of the preceding claims.

### Claim 12 (depends on 11)

The empty LNP of claim 11, wherein the empty LNP further comprises an ionizable lipid.

### Claim 13 (depends on 11, 12)

The empty LNP of claim 11 or 12, wherein the empty LNP further comprises a phospholipid.

### Claim 14 (depends on 11, 12, 13)

The empty LNP of any one of claims 11-13, wherein the empty LNP further comprises a structural lipid.

### Claim 15 (depends on 11, 12, 13, 14)

The empty LNP of any one of claims 11-14, wherein the empty LNP further comprises a PEG lipid.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A empty LNP comprising a lipid component which comprises from about 20 mol % to about 40 mol % of the compound of any one of claims 1-10; from about 15 mol % to about 40 mol % ionizable lipid, from about 0 mol % to about 30 mol % phospholipid, from about 15 mol % to about 50 mol % structural lipid, and from about 0 mol % to about 1 mol % PEG lipid.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

A loaded lipid nanoparticle (loaded LNP) comprising the empty LNP of any one of claims 11-16 and a therapeutic and/or prophylactic agent.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A loaded LNP comprising:
(a) a loaded LNP core comprising:
(i) an ionizable lipid,
(ii) a phospholipid,
(iii) a structural lipid, and
(iv) a PEG-lipid, and
(b) a therapeutic and/or prophylactic agent encapsulated within the core for delivery into a cell, and
(c) a cationic agent, wherein the cationic agent is a cationic lipid of any one of claims 1-10.

### Claim 19

A loaded LNP comprising:
(a) a loaded LNP core comprising:
(i) an ionizable lipid,
(ii) a phospholipid,
(iii) a structural lipid, and
(iv) a PEG-lipid, and
(b) a therapeutic and/or prophylactic agent encapsulated within the core for delivery into a cell, and
(c) a cationic agent.

### Claim 20 (depends on 19)

The loaded LNP of claim 19, wherein the cationic agent is a cationic lipid.

### Claim 21 (depends on 17, 18, 19, 20)

The loaded LNP of any one of claims 17-20, wherein the therapeutic and/or prophylactic agent is a nucleic acid.

### Claim 22 (depends on 21)

The loaded LNP of claim 21, wherein the therapeutic and/or prophylactic agent is a ribonucleic acid (RNA).

### Claim 23 (depends on 22)

The loaded LNP of claim 22, wherein the RNA is selected from the group consisting of a short interfering RNA (siRNA), an asymmetrical interfering RNA (aiRNA), a RNA interference (RNAi) molecule, a microRNA (miRNA), an antagomir, an antisense RNA, a ribozyme, a Dicer substrate RNA (dsRNA), a small hairpin RNA (shRNA), a messenger RNA (mRNA), and mixtures thereof.

### Claim 24 (depends on 23)

The loaded LNP of claim 23, wherein the RNA is an mRNA.

### Claim 25 (depends on 24)

The loaded LNP of claim 24, wherein the mRNA is a modified mRNA (mmRNA).

### Claim 26 (depends on 24, 25)

The loaded LNP of claim 24 or 25, wherein the mRNA incorporates a micro-RNA binding site (miR binding site).

### Claim 27 (depends on 24, 25, 26)

The loaded LNP of any one of claims 24-26, wherein the mRNA includes one or more of a stem loop, a chain terminating nucleoside, a polyA sequence, a polyadenylation signal, and/or a 5′ cap structure.

### Claim 28 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The empty LNP or loaded LNP of any one of claims 12-27, wherein the ionizable lipid is a compound of Formula (IL-A):
or its N-oxide, or a salt or isomer thereof, wherein:
R1 is selected from the group consisting of C5-30 alkyl, C5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;
R2 and R3 are independently selected from the group consisting of H, C1-14 alkyl, C2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R2 and R3, together with the atom to which they are attached, form a heterocycle or carbocycle;
R4 is selected from the group consisting of hydrogen, a C3-6 carbocycle, —(CH2)nQ, —(CH2)nCHQR, —(CH2)oC(R12)2(CH2)n-oQ, —CHQR, —CQ(R)2, —C(O)NQR and unsubstituted C1-6 alkyl, where Q is selected from a carbocycle, heterocycle, —OR, —O(CH2)nN(R)2, —C(O)OR, —OC(O)R, —OC(O)O—, —CX3, —CX2H, —CXH2, —CN, —N(R)2, —C(O)N(R)2, —N(R)C(O)R, —N(R)S(O)2R, —N(R)C(O)N(R)2, —N(R)C(S)N(R)2, —N(R)R′, —N(R)S(O)2R8, —O(CH2)nOR, —N(R)C(═NR9)N(R)2, —N(R)C(═CHR9)N(R)2, —OC(O)N(R)2, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)2R, —N(OR)C(O)OR, —N(OR)C(O)N(R)2, —N(OR)C(S)N(R)2, —N(OR)C(═NR9)N(R)2, —N(OR)C(═CHR9)N(R)2, —C(═NR9)N(R)2, —C(═NR9)R, —C(O)N(R)OR, —(CH2)nN(R)2 and —C(R)N(R)2C(O)OR, NRAS(O)2RSX, and
wherein A is a 3-14 membered heterocycle containing one or more heteroatoms selected from N, O and S; and a is 1, 2, 3, or 4; wherein
denotes a point of attachment;
each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5;
R8 is selected from the group consisting of C3-6 carbocycle and heterocycle;
R9 is selected from the group consisting of H, CN, NO2, C1-6 alkyl, —OR, —S(O)2R, —S(O)2N(R)2, C2-6 alkenyl, C3-6 carbocycle and heterocycle;
R12 is selected from the group consisting of H, OH, C1-3 alkyl, and C2-3 alkenyl;
each R is independently selected from the group consisting of C1-6 alkyl, C1-3 alkyl-aryl, C2-3 alkenyl, and H;
RA is selected from H and C1-3 alkyl;
RSX is selected from a C3-8 carbocycle, a 3-14 membered heterocycle containing one or more heteroatoms selected from N, O and S, C1-6 alkyl, C2-6 alkenyl, (C1-3 alkoxy)C1-3 alkyl, (CH2)p1O(CH2)p2RSX1, and (CH2)p1RSX1, wherein the carbocycle and heterocycle are optionally substituted with one or more groups selected from oxo, C1-6 alkyl, and (C1-3 alkoxy)C1-3 alkyl;
RSX1 is selected from C(O)NR14R14′, a C3-8 carbocycle, and a 3-14 membered heterocycle containing one or more heteroatoms selected from N, O and S, wherein the carbocycle and heterocycle are each optionally substituted with one or more groups selected from oxo, halo, C1-3 alkyl, (C1-3 alkoxy)C1-3 alkyl, C1-6 alkylamino, di-(C1-6 alkyl) amino, and NH2;
each R13 is selected from the group consisting of OH, oxo, halo, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C1-6 alkylamino, di-(C1-6 alkyl) amino, NH2, C(O)NH2, CN, and NO2;
R14 and R14′ are each independently selected from the group consisting of H and C1-6 alkyl;
p1 is selected from 1, 2, 3, 4, and 5;
p2 is selected from 1, 2, 3, 4, and 5;
each R5 is independently selected from the group consisting of OH, C1-3 alkyl, C2-3 alkenyl, and H;
each R6 is independently selected from the group consisting of OH, C1-3 alkyl, C2-3 alkenyl, and H;
R7 is selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
M and M′ are independently selected from —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)-M″-C(O)O—, —C(O)N(RM)—, —N(RM)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(O RM)O—, —S(O)2—, —S—S—, an aryl group, and a heteroaryl group, in which M″ is a bond, C1-13 alkyl or C2-13 alkenyl;
each RM is independently selected from the group consisting of H, C1-6 alkyl and C2-6 alkenyl;
each R′ is independently selected from the group consisting of C1-18 alkyl, C2-18 alkenyl, —R*YR″, —YR″, (CH2)q′OR*, and H,
and each q′ is independently selected from 1, 2, and 3;
each R″ is independently selected from the group consisting of C3-15 alkyl and C3-15 alkenyl;
each R* is independently selected from the group consisting of C1-12 alkyl and C2-12 alkenyl;
each Y is independently a C3-6 carbocycle;
each X is independently selected from the group consisting of F, Cl, Br, and I; and
m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

### Claim 29 (depends on 28)

The empty LNP or loaded LNP of claim 28, wherein the ionizable lipid is a compound of Formula (IL-B):
or its N-oxide, or a salt or isomer thereof, wherein:
R′a is R′branched; wherein R′branched is:
wherein
denotes a point of attachment;
wherein Raα, Raβ, Raγ, and Raδ are each independently selected from the group consisting of H, C2-12 alkyl, and C2-12 alkenyl;
R2 and R3 are each independently selected from the group consisting of C1-14 alkyl and C2-14 alkenyl;
R4 is selected from the group consisting of —(CH2)nOH, wherein n is selected from the group consisting of 1, 2, 3, 4, and 5, and
wherein
denotes a point of attachment; wherein
R10 is N(R)2; each R is independently selected from the group consisting of C1-6 alkyl, C2-3 alkenyl, and H; and n2 is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
each R5 is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
each R6 is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
M and M′ are each independently selected from the group consisting of —C(O)O— and —OC(O)—;
R′ is a C1-12 alkyl or C2-12 alkenyl;
l is selected from the group consisting of 1, 2, 3, 4, and 5; and
m is selected from the group consisting of 5, 6, 7, 8, 9, 10, 11, 12, and 13.

### Claim 30 (depends on 28)

The empty LNP or loaded LNP of claim 28, wherein the ionizable lipid is a compound of Formula (TL-C):
or a salt or isomer thereof, wherein
l is selected from 1, 2, 3, 4, and 5;
M1 is M′;
R4 is —(CH2)nQ, in which Q is OH, and n is selected from 1, 2, 3, 4, or 5;
M and M′ are independently selected from —C(O)O—, and —OC(O)—;
R2 and R3 are both C1-14 alkyl, or C2-14 alkenyl; and
R′ is a C1-C12 linear alkyl.

### Claim 31 (depends on 28)

The empty LNP or loaded LNP of claim 28, wherein the ionizable lipid is a compound of Formula (IL-D):
or its N-oxide, or a salt or isomer thereof,
wherein R′a is R′branched or R′cyclic; wherein
R′branched is
and R′b is:
wherein
denotes a point of attachment;
wherein Raγ is selected from the group consisting of C1-12 alkyl and C2-12 alkenyl;
R2 and R3 are each independently selected from the group consisting of C1-14 alkyl and C2-14 alkenyl;
R4 is —(CH2)nOH wherein n is selected from the group consisting of 1, 2, 3, 4, and 5;
R′ is a C1-12 alkyl or C2-12 alkenyl;
m is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9;
l is selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9.

### Claim 32 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The empty LNP or loaded LNP of any one of claims 12-27, wherein the ionizable lipid is a compound of Formula (IL-III):
or a salt or isomers thereof, wherein,
W is
ring A is
t is 1 or 2;
A1 and A2 are each independently selected from CH or N;
Z is CH2 or absent wherein when Z is CH2, the dashed lines (1) and (2) each represent a single bond; and when Z is absent, the dashed lines (1) and (2) are both absent;
R1, R2, R3, R4, and R5 are independently selected from the group consisting of C5-20 alkyl, C5-20 alkenyl, —R″MR′, —R*YR″, —YR″, and —R*OR″;
RX1 and RX2 are each independently H or C1-3 alkyl;
each M is independently selected from the group consisting of —C(O)O—, —OC(O)—, —OC(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)2—, —C(O)S—, —SC(O)—, an aryl group, and a heteroaryl group;
M* is C1-C6 alkyl,
W1 and W2 are each independently selected from the group consisting of —O— and —N(R6)—;
each R6 is independently selected from the group consisting of H and C1-5 alkyl;
X1, X2, and X3 are independently selected from the group consisting of a bond, —CH2—, —(CH2)2—, —CHR—, —CHY—, —C(O)—, —C(O)O—, —OC(O)—, —(CH2)n—C(O)—, —C(O)—(CH2)n—, —(CH2)n—C(O)O—, —OC(O)—(CH2)n—, —(CH2)n—OC(O)—, —C(O)O—(CH2)n—, —CH(OH)—, —C(S)—, and —CH(SH)—;
each Y is independently a C3-6 carbocycle;
each R* is independently selected from the group consisting of C1-12 alkyl and C2-12 alkenyl;
each R is independently selected from the group consisting of C1-3 alkyl and a C3-6 carbocycle;
each R′ is independently selected from the group consisting of C1-12 alkyl, C2-12 alkenyl, and H;
each R″ is independently selected from the group consisting of C3-12 alkyl, C3-12 alkenyl and —R*MR′; and
n is an integer from 1-6.

### Claim 33 (depends on 32)

The empty LNP or loaded LNP of claim 32, wherein the ionizable lipid is a compound of Formula (IL-IIIA):
or a salt or isomer thereof, wherein
R1, R2, R3, R4, and R5 are independently selected from the group consisting of C5-20 alkyl, C5-20 alkenyl, —R″MR′, —R*YR″, —YR″, and —R*OR″;
each M is independently selected from the group consisting of —C(O)O—, —OC(O)—, —OC(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)2—, an aryl group, and a heteroaryl group;
X1, X2, and X3 are independently selected from the group consisting of a bond, —CH2—, —(CH2)2—, —CHR—, —CHY—, —C(O)—, —C(O)O—, —OC(O)—, —C(O)—CH2—, —CH2—C(O)—, —C(O)O—CH2—, —OC(O)—CH2—, —CH2—C(O)O—, —CH2—OC(O)—, —CH(OH)—, —C(S)—, and —CH(SH)—;
each Y is independently a C3-6 carbocycle;
each R* is independently selected from the group consisting of C1-12 alkyl and C2-12 alkenyl;
each R is independently selected from the group consisting of C1-3 alkyl and a C3-6 carbocycle;
each R′ is independently selected from the group consisting of C1-12 alkyl, C2-12 alkenyl, and H; and
each R″ is independently selected from the group consisting of C3-12 alkyl and C3-12 alkenyl.

### Claim 34 (depends on 32, 33)

The empty LNP or loaded LNP of claim 32 or 33, wherein R1, R2, R3, R4, and R5 are each C5-20 alkyl; X1 is —CH2—; and X2 and X3 are each —C(O)—.

### Claim 35 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The empty LNP or loaded LNP of any one of claims 12-27, wherein the ionizable lipid is a compound selected from:

### Claim 36 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The empty LNP or loaded LNP of any one of claims 12-27, wherein the ionizable lipid is a compound selected from the compounds of Tables IL-1 to TL-7.

### Claim 37 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The empty LNP or loaded LNP of any one of claims 13-36, wherein the phospholipid is selected from the group consisting of
1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),
1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC),
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC),
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),
1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),
1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC),
1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC),
1,2-dilinolenoyl-sn-glycero-3-phosphocholine,
1,2-diarachidonoyl-sn-glycero-3-phosphocholine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine,
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),
1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE),
1,2-distearoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,
1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine,
1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG),
dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE),
distearoyl-phosphatidyl-ethanolamine (DSPE),
dipalmitoyl phosphatidyl ethanolamine (DPPE),
dimyristoylphosphoethanolamine (DMPE),
1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE),
1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC),
sphingomyelin, phosphatidylcholine, phosphatidylethanolamine,
phosphatidylserine,
phosphatidylinositol,
phosphatidic acid,
palmitoyloleoyl phosphatidylcholine,
lysophosphatidylcholine,
lysophosphatidylethanolamine (LPE)
sphingomyelin, and
mixtures thereof.

### Claim 38 (depends on 37)

The empty LNP or loaded LNP of claim 37, wherein the phospholipid is DSPC.

### Claim 39 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The empty LNP or loaded LNP of any one of claims 14-38, wherein the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.

### Claim 40 (depends on 39)

The empty LNP or loaded LNP of claim 39, wherein the structural lipid is
or a salt thereof.

### Claim 41 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The empty LNP or loaded LNP of any one of claims 15-40, wherein the PEG lipid is selected from the group consisting of a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.

### Claim 42 (depends on 41)

The empty LNP or loaded LNP of claim 41, wherein the PEG lipid is a compound of one of the following structures:
or a salt thereof, wherein r is an integer from 1 to 100; and s is an integer from 1 to 100.

### Claim 43 (depends on 42)

The empty LNP or loaded LNP of claim 42, wherein the PEG lipid is one of the following compounds:
or a salt thereof.

### Claim 44 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A pharmaceutical composition comprising the loaded LNP of any one of claims 17-43 and a pharmaceutically acceptable carrier.

### Claim 45 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of delivering a therapeutic and/or prophylactic agent to a cell within a subject, the method comprising administering to the subject the loaded LNP of any one of claims 17-43, or a pharmaceutical composition of claim 44.

### Claim 46 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of producing a polypeptide of interest in a cell within a subject, the method comprising administering to the subject the loaded LNP of any one of claims 17-43, or a pharmaceutical composition of claim 44.

### Claim 47 (depends on 45, 46)

The method of claim 45 or 46, wherein the cell is an endothelial cell.

### Claim 48 (depends on 47)

The method of claim 47, wherein the endothelial cell is a pulmonary endothelial cell, a respiratory endothelial cell, or a bronchial endothelial cell.

### Claim 49 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of specifically delivering a therapeutic and/or prophylactic agent to an organ of a subject, the method comprising administering to the subject the loaded LNP of any one of claims 17-43, or a pharmaceutical composition of claim 44.

### Claim 50 (depends on 49)

The method of claim 49, wherein the organ is the lung.

### Claim 51 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of specifically delivering a therapeutic and/or prophylactic agent to a tissue of a subject, the method comprising administering to the subject the loaded LNP of any one of claims 17-43, or a pharmaceutical composition of claim 44.

### Claim 52 (depends on 51)

The method of claim 51, wherein the tissue is the endothelium.

### Claim 53 (depends on 51)

The method of claim 51, wherein the tissue is the pulmonary endothelium.

### Claim 54 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the loaded LNP of any one claims 17-43, or a pharmaceutical composition of claim 44.

### Claim 55 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 45-54, wherein the administering is performed parenterally, intramuscularly, intradermally, subcutaneously, and/or intravenously.
